Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 12/2004

01-12-2004 | Original Paper

Reduced levels of the adenomatous polyposis coli (APC) protein are associated with ceramide-induced apoptosis of colon cancer cells

Authors: Aruna S. Jaiswal, Satya Narayan

Published in: Journal of Cancer Research and Clinical Oncology | Issue 12/2004

Login to get access

Abstract

Purpose

Mutations of the adenomatous polyposis coli (APC) and p53 genes are commonly found in colorectal cancers. We therefore analyzed the relative roles of APC and p53 in the induction of apoptosis of colon cancer cells by comparing the effects of the natural chemopreventive agent, C2-ceramide, on different human colon cancer cell lines with and without wild-type p53 and APC genes.

Methods

We studied the effect of C2-ceramide and C2-dihydroceramide on proliferation and/or apoptosis of colon cancer cell lines in vitro and determined the role of p53 and APC proteins in these processes. The protein and mRNA levels in colon cancer cell lines with and without treatments were determined by Western and Northern blot analysis, respectively. The cell cycle and apoptosis profiles were determined by FACS analysis and PARP-1 cleavage.

Results

Our findings indicate that C2-ceramide can induce apoptosis independently of the p53/p21(Waf-1/Cip-1) pathway. In addition, the C2-ceramide induction of apoptosis showed a correlation with a reduction in the levels of the APC protein and mRNA. Moreover, the C2-ceramide-induced apoptosis was blocked by pre-treatment with ZnCl2, which stabilizes APC protein levels.

Conclusions

These results suggest that C2-ceramide treatment reduces the levels of APC protein and that the reduction in the levels of this protein plays a key role in the ability of C2-ceramide to induce apoptosis of colon cancer cells.
Literature
Ahn EH, Schroeder JJ (2002) Sphingoid bases and ceramide induce apoptosis in HT-29 and HCT-116 human colon cancer cells. Exp Biol Med 227:345–353
Ames BN, Gold LS (1998) The causes and prevention of cancer: the role of environment. Biotherapy 11:205–220CrossRefPubMed
Berra B, Colombo I, Sottocornola E, Giacosa A (2002) Dietary sphingolipids in colorectal cancer prevention. Eur J Cancer Prev 11:193–197CrossRefPubMed
Browne SJ, MacFarlane M, Cohen GM, Paraskeva C (1998) The adenomatous polyposis coli protein and retinoblastoma protein are cleaved early in apoptosis and are potential substrates for caspases. Cell Death Differ 5:206–213CrossRefPubMed
Bruce WR, Giacca A, Medline A (2000) Possible mechanisms relating diet and risk of colon cancer. Cancer Epidemiol Biomarkers Prev 9:1271–1279PubMed
Bunz F, Hwang PM, Torrance C, Waldman T, Zhang Y, Dillehay L, Williams J, Lengauer C, Kinzler KW, Vogelstein B (1999) Disruption of p53 in human cancer cells alters the responses to therapeutic agents. J Clin Invest 104:263–269PubMed
Chan TA, Morin PJ, Vogelstein B, Kinzler KW (1998) Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 95:681–686CrossRefPubMed
Chauvier D, Morjani H, Manfait M (2002) Ceramide involvement in homocamptothecin- and camptothecin-induced cytotoxicity and apoptosis in colon HT29 cells. Int J Oncol 20:855–863PubMed
Dillehay DL, Webb SK, Schmelz EM, Merrill AH, Jr (1994) Dietary sphingomyelin inhibits 1,2-dimethylhydrazine-induced colon cancer in CF1 mice. J Nutr 124:615–620PubMed
Gartel AL, Tyner AL (2002) The role of the cyclin-dependent kinase inhibitor p21 in apoptosis. Mol Cancer Ther 1:639–649PubMed
Hannun YA (1997) In: Hannun YS (ed) Sphingolipid-mediated signal transduction. Landes Chapman & Hall, Austin, USA
Hasegawa S, Sato T, Akazawa H, Okada H, Maeno A, Ito M, Sugitani Y, Shibata H, Miyazaki Ji J, Katsuki M, Yamauchi Y, Yamamura Ki K, Katamine S, Noda T (2002) Apoptosis in neural crest cells by functional loss of APC tumor suppressor gene. Proc Natl Acad Sci USA 99:297–302CrossRefPubMed
Hotz MA, Gong J, Traganos F, Darzynkiewicz Z (1994) Flow cytometric detection of apoptosis: comparison of the assays of in situ DNA degradation and chromatin changes. Cytometry 15:237–244PubMed
Hursting SD (1997) Experimental models of gene-environment interaction for cancer chemoprevention studies. Curr Opin Oncol 9:487–491PubMed
Jaiswal AS, Bloom LB, Narayan S (2002a) Long-patch base excision repair of apurinic/apyrimidinic site DNA is decreased in mouse embryonic fibroblast cell lines treated with plumbagin: involvement of cyclin-dependent kinase inhibitor p21Waf-1/Cip-1. Oncogene 21:5912–5922CrossRefPubMed
Jaiswal AS, Marlow BP, Gupta N, Narayan S (2002b) Beta-catenin-mediated transactivation and cell-cell adhesion pathways are important in curcumin (diferuylmethane)-induced growth arrest and apoptosis in colon cancer cells. Oncogene 21:8414–8427CrossRefPubMed
Jaiswal AS, Narayan S (2004) Zinc stabilizes adenomatous polyposis coli (APC) protein levels and induces cell cycle arrest in colon cancer cells. J Cell Biochem (in press) (DOI 10.1002/jcb.20193)
Kelloff GJ, Boone CW, Steele VE, Crowell JA, Lubet R, Sigman CC (1994) Progress in cancer chemoprevention: perspectives on agent selection and short-term clinical intervention trials. Cancer Res 54 [Suppl]:2015s-2024s
Kishimoto Y, Morisawa T, Hosoda A, Shiota G, Kawasaki H, Hasegawa J (2002) Molecular changes in the early stage of colon carcinogenesis in rats treated with azoxymethane. J Exp Clin Cancer Res 21:203–211PubMed
Kok JW, Nikolova-Karakashian M, Klappe K, Alexander C, Merrill AH, Jr (1997) Dihydroceramide biology. Structure-specific metabolism and intracellular localization. J Biol Chem 272:21128–21136CrossRefPubMed
Kolesnick R (2002) The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J Clin Invest 110:3–8CrossRefPubMed
Kolesnick RN, Kronke M (1998) Regulation of ceramide production and apoptosis. Annu Rev Physiol 60:643–665CrossRefPubMed
Kolesnick RN, Goni FM, Alonso A (2000) Compartmentalization of ceramide signaling: physical foundations and biological effects. J Cell Physiol 184:285–300CrossRefPubMed
Liu MC, Gelmann EP (2002) p53 gene mutations: case study of a clinical marker for solid tumors. Semin Oncol 29:246–257CrossRefPubMed
Marnett LJ, DuBois RN (2002) COX-2: a target for colon cancer prevention Annu Rev Pharmacol Toxicol 42:55–80
Modrak DE, Rodriguez MD, Goldenberg DM, Lew W, Blumenthal RD (2002) Sphingomyelin enhances chemotherapy efficacy and increases apoptosis in human colonic tumor xenografts. Int J Oncol 20:379–384PubMed
Morin PJ, Vogelstein B, Kinzler KW (1996) Apoptosis and APC in colorectal tumorigenesis. Proc Natl Acad Sci USA 93:7950–7954CrossRefPubMed
Narayan S, Jaiswal, AS (1997) Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N’-nitro-N-nitrosoguanidine requires p53. J Biol Chem 272:30619–30622CrossRefPubMed
Obeid LM, Linardic CM, Karolak LA, Hannun YA (1993) Programmed cell death induced by ceramide. Science 259:1769–1771PubMed
Okazaki T, Bielawska A, Bell RM, Hannun YA (1990) Role of ceramide as a lipid mediator of 1-alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. J Biol Chem 265:15823–15831PubMed
Oren M, Damalas A, Gottlieb T, Michael D, Taplick J, Leal JF, Maya R, Moas M, Seger R, Taya Y, Ben-Ze’ev A (2002) Regulation of p53: intricate loops and delicate balances. Biochem Pharmacol 64:865–871CrossRefPubMed
Oshima M, Taketo MM (2002) COX selectivity and animal models for colon cancer. Curr Pharm Des 8:1021–1034PubMed
Parodi PW (1997) Fat components as potential anticarcinogenic agents. J Nutr 127:1055–1060PubMed
Prajapati S, Gaynor RB (2002) Regulation of Ikappa B kinase (IKK) gamma /NEMO function by IKKbeta -mediated phosphorylation. J Biol Chem 277:24331–24339CrossRefPubMed
Rezvani M, Liew CC (2000) Role of the adenomatous polyposis coli gene product in human cardiac development and disease. J Biol Chem 275:18470–18475CrossRefPubMed
Ries LAG, Eisner MP, Kosary CL, Hankey BF, Miller BA, Clegg L, Edwards BK (2002) SEER Cancer statistics review, 1973–1999. National Cancer Institute, Bethesda, USA
Schmelz EM, Dillehay DL, Webb SK, Reiter A, Adams J, Merrill AH, Jr (1996) Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res 56:4936–4941PubMed
Schmelz EM, Bushnev AS, Dillehay DL, Liotta DC, Merrill AH, Jr (1997) Suppression of aberrant colonic crypt foci by synthetic sphingomyelins with saturated or unsaturated sphingoid base backbones. Nutr Cancer 28:81–85PubMed
Schmelz EM, Sullards MC, Dillehay DL, Merrill AH, Jr (2000) Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1, 2-dimethylhydrazine-treated CF1 mice. J Nutr 130:522–527PubMed
Schmelz EM, Roberts PC, Kustin EM, Lemonnier LA, Sullards MC, Dillehay DL, Merrill AH, Jr (2001) Modulation of intracellular beta-catenin localization and intestinal tumorigenesis in vivo and in vitro by sphingolipids. Cancer Res 61:6723–6729PubMed
Selzner M, Bielawska A, Morse MA, Rudiger HA, Sindram D, Hannun YA, Clavien PA (2001) Induction of apoptotic cell death and prevention of tumor growth by ceramide analogues in metastatic human colon cancer. Cancer Res 61:1233–1240PubMed
Sinha R (2002) An epidemiologic approach to studying heterocyclic amines. Mutat Res 506–507:197–204
Slattery ML (2000) Diet, lifestyle, and colon cancer. Semin Gastrointest Dis 11:142–146PubMed
Tewari M, Quan LT, O’Rourke K, Desnoyers S, Zeng Z, Beidler DR, Poirier GG, Salvesen GS, Dixit VM (1995) Yama/CPP32 beta, a mammalian homolog of CED-3, is a CrmA-inhibitable protease that cleaves the death substrate poly(ADP-ribose) polymerase. Cell 81:801–809CrossRefPubMed
van Es JH, Giles RH, Clevers HC (2001) The many faces of the tumor suppressor gene APC. Exp Cell Res 264:126–134CrossRefPubMed
Veldman RJ, Klappe K, Hoekstra D, Kok JW (1998) Metabolism and apoptotic properties of elevated ceramide in HT29rev cells. Biochem J 331:563–569PubMed
Vesper H, Schmelz EM, Nikolova-Karakashian MN, Dillehay DL, Lynch DV, Merrill AH, Jr (1999) Sphingolipids in food and the emerging importance of sphingolipids to nutrition. J Nutr 129:1239–1250PubMed
Yamamoto Y, Gaynor RB (2001) Therapeutic potential of inhibition of the NF-kappaB pathway in the treatment of inflammation and cancer. J Clin Invest 107:135–142
Yamamoto Y, Yin MJ, Lin KM, Gaynor RB (1999) Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem 274:27307–27314CrossRefPubMed
Yu HG, Huang JA, Yang YN, Huang H, Luo HS, Yu JP, Meier JJ, Schrader H, Bastian A, Schmidt WE, Schmitz F (2002) The effects of acetylsalicylic acid on proliferation, apoptosis, and invasion of cyclooxygenase-2 negative colon cancer cells. Eur J Clin Invest 32:838–846CrossRefPubMed
Metadata
Title
Reduced levels of the adenomatous polyposis coli (APC) protein are associated with ceramide-induced apoptosis of colon cancer cells
Authors
Aruna S. Jaiswal
Satya Narayan
Publication date
01-12-2004
Publisher
Springer-Verlag
Published in
Journal of Cancer Research and Clinical Oncology / Issue 12/2004
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-004-0591-6

Other articles of this Issue 12/2004

Journal of Cancer Research and Clinical Oncology 12/2004 Go to the issue

Original Paper

Increase of interleukin-18 serum levels after engraftment correlates with acute graft-versus-host disease in allogeneic peripheral blood stem cell transplantation

Original Paper

Thrombocytopenia associated with second-line carboplatin-based chemotherapy for ovarian, fallopian tube, and primary peritoneal cavity cancers

Original Paper

Significance of isolated tumor cells in lymph nodes among gastric cancer patients

Original Paper

KIAA0008 gene is associated with invasive phenotype of human hepatocellular carcinoma—a functional analysis

Original Paper

Signal transduction of c-Kit receptor tyrosine kinase in CHRF myeloid leukemia cells

Original Paper

Orbital metastases in breast cancer: report of two cases and review of the literature
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits